Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
- Author:
Jing-Pu YANG
1
;
Yan LIU
;
Wei ZHONG
;
Dan YU
;
Lian-Ji WEN
;
Chun-Shun JIN
Author Information
- Publication Type:Journal Article
- MeSH: AC133 Antigen; ATP Binding Cassette Transporter, Sub-Family G, Member 2; ATP-Binding Cassette Transporters; genetics; metabolism; Antigens, CD; genetics; metabolism; Antineoplastic Agents; pharmacology; Blotting, Western; Carcinoma; genetics; metabolism; Cell Line, Tumor; Cisplatin; pharmacology; Flow Cytometry; Fluorouracil; pharmacology; Glycoproteins; genetics; metabolism; Humans; Laryngeal Neoplasms; genetics; metabolism; Neoplasm Proteins; genetics; metabolism; Neoplastic Stem Cells; cytology; drug effects; metabolism; Paclitaxel; pharmacology; Peptides; genetics; metabolism; Reverse Transcriptase Polymerase Chain Reaction
- From: Chinese Medical Journal 2011;124(7):1055-1060
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDMounting evidence suggests that tumors are histologically heterogeneous and are maintained by a small population of tumor cells termed cancer stem cells. CD133 has been identified as a candidate marker of cancer stem cells in laryngeal carcinoma. This study aimed to analyze the chemoresistance of CD133(+) cancer stem cells.
METHODSThe response of Hep-2 cells to different chemotherapeutic agents was investigated and the expression of CD133 was studied. Fluorescence-activated cell sorting analysis was used to identify CD133, and the CD133(+) subset of cells was separated and analyzed in colony formation assays, cell invasion assays, chemotherapy resistance studies, and analyzed for the expression of the drug resistance gene ABCG2.
RESULTSAbout 1% - 2% of Hep-2 cells were CD133(+) cells, and the CD133(+) proportion was enriched by chemotherapy. CD133(+) cancer stem cells exhibited higher potential for clonogenicity and invasion, and were more resistant to chemotherapy. This resistance was correlated with higher expression of ABCG2.
CONCLUSIONSThis study suggested that CD133(+) cancer stem cells are more resistant to chemotherapy. The expression of ABCG2 could be partially responsible for this. Targeting this small population of CD133(+) cancer stem cells could be a strategy to develop more effective treatments for laryngeal carcinoma.
